Zofran Energy Drinks
Scientific findings indicate that highly-caffeinated energy drinks may cause significant morbidity in adolescents from elevated blood pressure, brain seizures, and severe cardiac events. Disturbingly, it seems, Monster Beverage Corp., as well as other energy drink companies, are targeting marketing efforts toward children. The FDA has investigated the health risks of these products to vulnerable groups, including children and those with pre-existing cardiac conditions.
Contact us if you or a loved one has suffered an injury following the consumption of an Energy drink. We may arrange a free telephone consultation.
For more information from the FDA about Energy Drinks use the following resources:
Voluntary and Mandatory Reports on 5-Hour Energy, Monster Energy, and Rockstar Energy Drink
Energy “Drinks” and Supplements: Investigations of Adverse Event Reports
Zofran is an anti-nausea drug approved to treat nausea and vomiting in chemotherapy and surgery patients, however, it has been marketed and used “off-label” to treat severe morning sickness in pregnant women, and is not approved to be used during pregnancy. Some mothers who used the drug within the first trimester have discovered their child with birth defects, such as, cleft lip, cleft palate, and congenital heart defects.
The FDA has classified it as a “Pregnancy Category B” drug. Animal studies have not found evidence of a risk, but no one knows if it is safe.
Contact us if you or someone you know had a child with a birth defect such as cleft lip or palate or congenital heart defects following early prenatal exposure to Zofran. We may arrange a free telephone consultation.
For more information about Zofran use the following resources:
Use of ondansetron during pregnancy and congenital malformations in the infant
GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data
Xarelto is a blood thinner used primarily for the prevention of stroke and systematic embolism in patients with nonvalvular atrial fibrillation. Patients may be at an increased risk of suffering major bleeding events and strokes, particularly with no blood monitoring. Disturbingly, it appears the drug maker placed more value on profits than on minimizing the serious and fatal injuries resulting from Xarelto when proper drug monitoring does not occur.
Contact us if you or a loved one has suffered from internal bleeding, DVT, stroke, or death while on Xarelto. We may arrange a free telephone consultation.
For more information from the FDA about Xarelto use the following resource:
Initial FDA Concerns about Xarelto